HR 8857 — Next GEN Act of 2026
Last action — Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
-
✓Introduced
-
2In Committee
-
3Passed House
-
4Passed Senate
-
5To Executive
-
6Enacted
This bill is in committee in the House. Introduced May 15, 2026. It must pass committee before a floor vote.
Next likely step: a committee vote, then a floor vote in the House.
Odds of enactment
Low chanceBased on the sponsor, cosponsors, and committee posture, this bill has a low chance of becoming law.
Upgrade to see the exact probability and what's driving it.
A statistical estimate from our own model of past outcomes — an insight, not a guarantee. Policymaking is volatile.
Prognosis
-
In Committee
Current position in the legislative process.
-
4 sponsors
1 primary, 3 co-sponsors signed on.
-
Bipartisan support
Sponsored across 2 parties (2 D · 2 R) — cross-party backing.
Based on stage, sponsorship breadth, committee status, recorded votes, and cross-state momentum — a description of the observable signals, not a prediction.
In plain language
The bill updates which engineered cyclic peptides can be negotiated under the Drug Price Negotiation Program.
This legislation modifies the definition of qualifying engineered cyclic peptides for drug price negotiations, lengthening the exclusivity period to 11 years. It aims to clarify the criteria for these specific drugs in the Medicare program.
What this means for you
- Healthcare: This may affect healthcare providers involved in prescribing engineered cyclic peptides.
Bill Text
- Introduced Introduced in House Current html May 15, 2026
Action History
-
Introduced in House
-
Introduced in House
-
Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
-
Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Sponsors
- Josh Gottheimer · Cosponsor
- August Pfluger · Cosponsor
- Thomas H. Kean · Cosponsor
- Joseph D. Morelle · Primary
Sponsorship breakdown
Export CSV (upgrade) →1 sponsors · 3 co-sponsors · 543 not signed on
Sponsors (1)
- Morelle, Joseph D. Democratic
Co-sponsors (3)
- Gottheimer, Josh Democratic
- Pfluger, August Republican
- Kean, Thomas H. Republican
Not signed on (543)
543 members have not signed on to this bill.
Show all 543 →"Not signed on" means a member has not sponsored or co-sponsored this bill — it does not imply opposition. Members flagged Voted No have a recorded No vote on this bill.
Subjects
Frequently asked questions
- Who sponsors HR 8857?
- HR 8857 is sponsored by Gottheimer, Josh (Democratic), Pfluger, August (Republican), Kean, Thomas H. (Republican), and Morelle, Joseph D. (Democratic).
- What is the current status of HR 8857?
- This bill is in committee in the House. Introduced May 15, 2026. It must pass committee before a floor vote.
- Where can I track HR 8857?
- Track HR 8857 free on One Click Politics — get push/email alerts when it moves.
Make your voice heard on HR 8857
Find the representatives who decide this bill and tell them where you stand — for yourself, or mobilize your whole list in one click with One Click Politics advocacy software.
Stay ahead of HR 8857
Last checked for changes 3 months ago · updated continuously
One Click Politics tracks every bill in Congress and all 50 states.
Track this bill →